logo-loader
viewOpen Orphan PLC

Venn Life Sciences boss hopes to secure more million euro contracts

Tony Richardson, chief executive of Venn Life Sciences (LON:VENN), says the clinical research organisation’s key objective is to pitch for bigger pieces of business resulting in significant multi-million euro contracts.

Richardson’s prediction follows the announcement of a €1mln contract from a French biotech.  Venn has worked with the unnamed client on a previous clinical trial and Richardson says more large repeat contracts make the delivery of future growth ‘a little easier.’

Quick facts: Open Orphan PLC

Price: 14.63 GBX

AIM:ORPH
Market: AIM
Market Cap: £86.83 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Innovenn split will ‘maximise shareholder value’, says Venn CEO

Venn Life Sciences Holdings plc (LON:VENN) chief executive Tony Richardson says that separating Innovenn from its core business simplifies the firm and generates more value for shareholders. Speaking exclusively to Proactive, Richardson says: “Spinning [Innovenn] out, we believe, will...

on 5/10/16

2 min read